This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Patients with a history of multisystem inflammatory syndrome in children (MIS-C) completed a questionnaire about adversereactions following COVID-19 vaccination, and no serious adverseevents were recorded.
It’s a bleak day in the fight against COVID-19, after the UK banned social gatherings of more than six people to contain growing numbers of new cases and the lead vaccine trial from AstraZeneca was halted because of a safety concern.
Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. The vaccine is indicated for active immunisation to prevent the disease.
Novavax and Serum Institute of India (SII) have reported that the former’s Covid-19 vaccine, NVX-CoV2373, has received full product registration from the South African Health Products Regulatory Authority (SAHPRA), with conditions. The vaccine showed efficacy, with an encouraging safety and tolerability profile, in the trials. .
US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adversereaction in one patient who received the shot. There are many possible factors that could have caused the event.”.
1 But while data on adversereactions is rightly used to help with these decisions, there is currently no additional modelling on the positive impact regulatory action could have on public health. Researchers also study the long-term effects of medicines and vaccines, as well as the safety of new and advanced products.
Many drug interactions are related to additive adversereaction profiles with concomitant medications with similar side effect profiles. In the event of any sign of bleeding, seek immediate medical advice. Still, there are also interactions based on the mechanism of metabolism by the body.
Treatment and care of patients with high-risk NMIBC, including those with CIS often involves removing the tumour and the use of the BCG vaccine to reduce the risk that the cancer will recur. Few effective treatment options exist for patients who develop BCG-unresponsive disease. Clinical study of Adstiladrin.
AstraZeneca’s decision to halt all its phase 3 trials of COVID-19 vaccine AZD1222 after an adversereaction in a single UK volunteer may end up just being a precautionary, but could still see the shot fall behind vaccines from rival developers.
A new test is being developed for MAP detection in support of a vaccine for Crohn’s disease; it has been in clinical trials, and looks very promising. Researchers found they could suppress the autoimmune response if using a vaccine or antibiotic that specifically eradicates E. In one study, genetically susceptible mice with E.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content